As Its Rivals Team Up, Editas Buys Next-Gen CRISPR From Old Friends – Xconomy
Xconomy |
As Its Rivals Team Up, Editas Buys Next-Gen CRISPR From Old Friends
Xconomy Instead of using the enzyme Cas9 to snip out defective genes inside a cell, the new system uses the enzyme Cpf1. CRISPR–Cpf1 was first described in a paper published in the journal Cell last year, as Xconomy reported. The paper's authors, including the … Editas licenses new gene-editing tool, raising stakes in drug development race Editas Expands CRISPR Capabilities through New Technology Licensing Editas Medicine Inks Licensing Deals for CRISPR IP |
